NEW YORK (GenomeWeb) – Roche announced this week that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta for $27 per share. The tender offer is being made pursuant to a merger agreement entered into by Ignyta and Roche on Dec. 21, and will expire on Feb. 7. Following successful completion of the tender offer, any shares not acquired will be acquired in a second step merger at the same price of $27 per share. The closing of the transaction is expected to take place in the first half of 2018.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.